Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

All news

Show

From To
Thousands register for new hepatitis C drug in Egypt sold at 99 percent discount

On Thursday, Gamal Esmat, member of the Egyptian National Committee on Viral Hepatitis told Aswat Masriya that around 1,7000 people had registered hours after online registration opened on the Health Ministry’s website.

Published
19 September 2014
From
Egyptian Streets
Stigma, ambivalence and other priorities – explaining poor adherence to PrEP and vaginal microbicides

HIV stigma, the danger of being mistakenly labelled as having HIV, ambivalence about the research process, confusion about the use of antiretrovirals to prevent infection, as well

Published
19 September 2014
By
Roger Pebody
US: How Insurers Are Finding Ways to Shift Costs to the Sick

Health insurance companies are no longer allowed to turn away patients because of their pre-existing conditions or charge them more because of those conditions. But some health policy experts say insurers may be doing so in a more subtle way: by forcing people with a variety of illnesses — including Parkinson’s disease, diabetes and epilepsy — to pay more for their drugs.

Published
18 September 2014
From
New York Times
PREZCOBIX™ now available for Canadians living with HIV

Janssen Inc. announced today that PREZCOBIX™ (darunavir/cobicistat), a once-daily, oral medication for the treatment of HIV infection in combination with other antiretroviral agents, is now available in Canada. The new treatment option combining a protease inhibitor with a boosting agent reduces the number of pills required to manage HIV.

Published
18 September 2014
From
Newswire.ca
San Francisco Official Says He Takes Truvada to Prevent H.I.V., and More Gay Men Should, Too

Scott Wiener, a member of the San Francisco Board of Supervisors, made an unusual public announcement on Wednesday: He takes Truvada, a daily antiviral pill, to greatly reduce his risk of contracting HIV.

Published
18 September 2014
From
New York Times
CDC Launches HIV Treatment Awareness Campaign

“HIV Treatment Works” is a new awareness campaign from the U.S. Centers for Disease Control and Prevention (CDC).

Published
17 September 2014
From
Poz
Community Leaders, HIV Doctors Oppose Hepatitis C Treatment Barriers

A coalition of hepatitis C advocacy organizations and medical providers has issued an open letter to the Secretary of Health and Human Services calling for an end to restrictions on access to hepatitis C treatment by private insurers and public payers seeking to avoid the cost of newly approved direct-acting antivirals. HIV medical providers also called for reducing barriers to treatment, including restrictions on which medical specialists may treat people with hepatitis C.

Published
17 September 2014
From
HIVandhepatitis.com
Houston we have an HIV PR problem

The most important group who should hear about treatment as prevention, undetectability, sero-sorting and all the other non-condom options, are those who have successfully avoided HIV thus far and are reluctant to get tested. In other words the vast majority of the LGBT population, because they are the ones who are getting the wrong end of the stick when they hear snippets of information about HIV.

Published
17 September 2014
From
Positive Lite
Gilead’s Proposed Hepatitis C Medicines License: How Badly Will it Miss the Target?

Gilead’s proposed license, and its limitations, is important because Gilead has applied for patents on Sovaldi® and ledipasvir in many countries, although a number of countries in the probable licensed territory are without patents. As a patent holder, Gilead generally has rights to exclude competitors and charge monopoly prices on these life-saving medicines. The anticipated license will set precise terms on which companies can make generic equivalents and where and under what circumstances those generics can be sold. In other words, Gilead sits in the driver’s seat and has enormous power to decide who does and doesn’t get more affordable access to generics of assured quality.

Published
17 September 2014
From
Infojustice
Access to sofosbuvir in middle-income countries

Gilead is excluding 51 middle income countries (MICs) from its license for sofosbuvir, an oral hepatitis C drug. Across these MICs, where nearly 50 million people are infected with hepatitis C virus (HCV), lack of access to generic sofosbuvir will increase the total cost of curing hepatitis C by an estimated $60 billion dollars, according to I-MAK’s analysis.

Published
17 September 2014
From
I-MAK
← First12345...1792Next →

Filter by country